News25/Ratings10
Price$50.67-50.67 (-50.00%)
2026-01-202026-04-23
News · 26 weeks67-25%
2025-10-262026-04-19
Mix4090d
- Other12(30%)
- Insider12(30%)
- SEC Filings8(20%)
- Analyst4(10%)
- Earnings3(8%)
- Leadership1(3%)
Latest news
25 items- PRGRAIL to Announce First Quarter 2026 Financial ResultsMENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2026 following the close of market on Tuesday, May 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. First Quarter 2026 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the investor
- PRGRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual MeetingDetailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation More than 174,000 Participants Enrolled Across Both Studies, Demonstrating the Scientific Rigor of Galleri® Clinical Development ProgramMENLO PARK, Calif., April 21, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the 2026 American Society of Cl
- INSIDERSEC Form 4 filed by Summe Gregory L4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by Chase William J4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by Mizell Steven4 - GRAIL, Inc. (0001699031) (Issuer)
- ANALYSTMizuho initiated coverage on GRAIL with a new price targetMizuho initiated coverage of GRAIL with a rating of Neutral and set a new price target of $58.00
- INSIDERSEC Form 4 filed by Ragusa Robert P4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by Freidin Aaron4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by Ofman Joshua J.4 - GRAIL, Inc. (0001699031) (Issuer)
- PRGRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access NationwideIntegration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient PortalCollaboration With Epic Will Allow Clinicians to Seamlessly Order the Galleri Multi-Cancer Early Detection Test at the Point of CareMENLO PARK, Calif., April 7, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Epic to bring the Galleri® multi-cancer early detection test into one of the nation's most widely used electronic health record (EHR) platforms, supporting broader adoption across health systems in the United States.
- SECSEC Form 144 filed by GRAIL Inc.144 - GRAIL, Inc. (0001699031) (Subject)
- PRCancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early DetectionPartnership expands access to breakthrough blood-based cancer screening intoSuperpower's comprehensive health check and personalized plans.SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- Superpower, the first all-in-one proactive health platform, announced a strategic partnership with GRAIL, Inc. (NASDAQ:GRAL) to bring members access to the Galleri® multi-cancer early detection (MCED) test. Timed with the start of National Cancer Prevention and Early Detection Month, the partnership reflects a shared belief that cancer detection must evolve to meet a changing reality — removing traditional barriers to advanced testing and putting earlier insight, data, and control directly in people's hands.
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)
- ANALYSTGRAIL upgraded by TD Cowen with a new price targetTD Cowen upgraded GRAIL from Hold to Buy and set a new price target of $65.00
- SECSEC Form S-8 filed by GRAIL Inc.S-8 - GRAIL, Inc. (0001699031) (Filer)
- SECSEC Form 10-K filed by GRAIL Inc.10-K - GRAIL, Inc. (0001699031) (Filer)
- PRGRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as SuccessorMENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to serve as GRAIL's Chief Executive Officer upon Ragusa's retirement. In addition, Ofman has been appointed to GRAIL's Board of Directors, effective immediately. Ofman's appointment is the culmination of a long-term comprehensive succession planning process to ensure leadership continuity and strategic execution. Ragusa will remain on GRAIL's Board unti
- INSIDERChief Financial Officer Freidin Aaron sold $154,062 worth of shares (3,147 units at $48.96), decreasing direct ownership by 1% to 306,475 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERPresident Ofman Joshua J. sold $177,227 worth of shares (3,627 units at $48.86), decreasing direct ownership by 0.83% to 432,881 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERChief Executive Officer Ragusa Robert P sold $409,246 worth of shares (8,441 units at $48.48), decreasing direct ownership by 1% to 642,084 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- SECSEC Form 144 filed by GRAIL Inc.144 - GRAIL, Inc. (0001699031) (Subject)
- SECSEC Form 144 filed by GRAIL Inc.144 - GRAIL, Inc. (0001699031) (Subject)
- INSIDERPresident Ofman Joshua J. was granted 84,540 shares and sold $852,848 worth of shares (17,002 units at $50.16), increasing direct ownership by 18% to 436,508 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERChief Financial Officer Freidin Aaron was granted 60,118 shares and sold $480,244 worth of shares (9,573 units at $50.17), increasing direct ownership by 20% to 309,622 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERChief Executive Officer Ragusa Robert P sold $1,881,417 worth of shares (37,504 units at $50.17), decreasing direct ownership by 5% to 650,525 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)